While its ~12.4% average weight loss at the highest dose might appear lower than some Semaglutide data points, a key head-to-head trial in Type 2 Diabetes (ACHIEVE-3) showed orforglipron to be superior to oral semaglutide (7mg and 14mg doses) in both A1C reduction and weight loss over 52 weeks
Good candidates for semaglutide typically have a BMI of 30 or higher, or a BMI of 27 or higher with weight-related health conditions like high blood pressure, type 2 diabetes, or high cholesterol
The data figured into an average weight loss of 50.3 pounds (22.8 kg) for patients on Zepbound and 33.1 pounds (15 kg) for those who received Wegovy
Both drugs were well tolerated: overall less than 10% of patients discontinued treatment due to the occurrence of side effects, with no significant differences between the two formulations, despite a slightly higher discontinuation rate in oral semaglutide group
The fold change in the apparent permeability coefficient of semaglutide elicited by SNAC was rapidly reduced following the removal of SNAC (within 60 min), emphasising its relatively short window of action
Meyer, L
